TY  - GEN
AU  - Molina-Molina, M
AU  - Machahua-Huamani, C
AU  - Vicens-Zygmunt, V
AU  - Llatjos, R
AU  - Escobar, I
AU  - Sala Llinàs, Ernest
AU  - Luburich-Hernaiz, P
AU  - Dorca, J
AU  - Montes-Worboys, A
PY  - 2018
DO  - 10.1186/s12890-018-0626-4
SN  - 1471-2466
UR  - https://hdl.handle.net/20.500.12105/22534
AB  - Background: Pirfenidone, a pleiotropic anti-fibrotic treatment, has been shown to slow down disease progression of idiopathic pulmonary fibrosis (IPF), a fatal and devastating lung disease. Rapamycin, an inhibitor of fibroblast proliferation could be...
LA  - eng
PB  - BioMed Central (BMC)
KW  - Pirfenidone
KW  - Rapamycin
KW  - Idiopathic pulmonary fibrosis
KW  - Pulmonary fibrosis
KW  - Cell migration
KW  - Extracellular matrix proteins
KW  - Epithelial-mesenchymal transition
KW  - Alveolar Epithelial Cells
KW  - Biomarkers
KW  - Extracellular Matrix
KW  - Epithelial-Mesenchymal Transition
KW  - Idiopathic Pulmonary Fibrosis
KW  - Myofibroblasts
KW  - Pyridones
KW  - Cell Movement
KW  - Humans
KW  - Transforming Growth Factor beta1
KW  - A549 Cells
KW  - Sirolimus
TI  - Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells
TY  - research article
ER  -